Teva Pharmaceutical Industries LTD

Teva Pharmaceutical Industries Ltd. announced robust second-quarter 2026 financial results, driven by significant growth in its key innovative brands, leading to an upward revision of its full-year outlook.

Teva Pharmaceutical Industries Limited shareholders approved the election of Dr. Sol J. Barer to the Board and ratified executive compensation and auditor appointments.

Teva Pharmaceutical Industries Ltd. announced robust first-quarter 2026 financial results driven by its innovative portfolio and disciplined execution, alongside a definitive agreement to acquire Emalex Biosciences for its neuroscience pipeline.

Teva Pharmaceutical Industries Ltd. announced its 2025 financial results, marking a third consecutive year of growth driven by its innovative brands and strategic execution.

Teva Pharmaceutical Industries Ltd. presented its 'Pivot to Growth' strategy, 2025 financial expectations, and long-term targets through 2030 at the J.P. Morgan Healthcare Conference.

Teva Pharmaceutical Industries Limited secured an extension of its revolving credit facility maturity date to April 2028 and amended financial covenants, including a suspension clause for investment-grade status.

Teva Pharmaceutical Industries Limited announced amendments to its deposit agreement and the termination of its American Depositary Shares (ADS) program, with ordinary shares to be directly listed on the NYSE.

Teva Pharmaceutical Industries Limited reported a significant turnaround in Q3 2025, achieving net income and operating profit, driven by strong U.S. segment performance and substantial debt reduction.

Teva Pharmaceutical Industries Limited announced a significant increase in operating income and net income for the second quarter of 2025, driven by robust performance in its U.S. segment and strategic debt management, despite a slight revenue decrease in local currency terms.

Teva Pharmaceutical Industries reports a 2% increase in revenue for Q1 2025, driven by growth in AUSTEDO, generics, and AJOVY, while progressing with its Pivot to Growth strategy.

Teva Pharmaceutical Industries reported a 13% increase in revenue for the third quarter of 2024, but also faced a significant goodwill impairment and increased legal expenses.

Teva Pharmaceutical Industries reports a 7% revenue increase in Q2 2024, but also records a significant goodwill impairment charge.

Teva Pharmaceutical Industries Limited reported a 4% increase in 2025 revenues, driven by strong performance in key innovative products and strategic pipeline advancements, despite declines in certain generic markets.

Teva Pharmaceutical Industries navigates a year of strategic transformation, showcasing growth in key products but facing challenges in generics and legacy treatments.

Teva Pharmaceuticals extends an executive's international assignment and revises prior financial statements, highlighting a collaboration payment and sustainability-linked bond details.

Teva Pharmaceutical Industries Ltd. CFO Eliyahu Sharon Kalif sold a portion of his holdings in ordinary shares as part of a pre-arranged trading plan.

Teva Pharmaceuticals Director Sol J. Barer reported a transaction involving ordinary shares and restricted share units on June 5, 2026.

Chen Lichtenstein, a Director at Teva Pharmaceutical Industries Ltd., reported transactions involving ordinary shares and restricted share units.

Rosemary A. Crane, a Director at TEVA Pharmaceutical Industries Ltd., reported transactions involving ordinary shares and restricted share units.

Teva Pharmaceutical Industries Ltd. director Amir Elstein has reported the acquisition of 14,492 ordinary shares through restricted share units that vested on June 5, 2026.

Teva Pharmaceutical Industries Ltd. director Perry Nisen has reported the acquisition of 14,492 ordinary shares through the vesting of restricted share units.

Teva Pharmaceutical Industries Limited reports strong 2025 performance, advancing its 'Pivot to Growth' strategy with significant gains in innovative medicines and debt reduction, while outlining ambitious 2026 goals.

Teva Pharmaceutical Industries Limited will hold its annual shareholder meeting virtually on June 5, 2025, to vote on director elections, executive compensation, and other key proposals.

Teva Pharmaceutical Industries is asking shareholders to vote on key proposals at its upcoming annual meeting, including the election of directors, executive compensation, and amendments to director compensation policies.

Teva Pharmaceutical Industries Limited will hold its annual shareholder meeting virtually on June 6, 2024, to vote on director appointments, executive compensation, and auditor selection.

Teva Pharmaceutical's proxy statement highlights the company's 'Pivot to Growth' strategy, board refreshment, and key proposals for the 2024 annual meeting.

Migdal Insurance & Financial Holdings Ltd. has reported a beneficial ownership of 5.37% in Teva Pharmaceutical Industries Ltd. as of December 31, 2025.

Harel Insurance Investments & Financial Services Ltd. has reported a 6.3% beneficial ownership stake in Teva Pharmaceutical Industries Ltd. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 2.1% beneficial ownership stake in Teva Pharmaceutical Industries Ltd. as of September 30, 2025.

Harel Insurance Investments & Financial Services Ltd has reported a 5.1% beneficial ownership stake in Teva Pharmaceutical Industries Ltd, primarily held on behalf of public and client accounts.

FMR LLC and Abigail P. Johnson report a 5.1% beneficial ownership of Teva Pharmaceutical Industries Ltd. common stock.

Phoenix Financial Ltd. has reported a 5% beneficial ownership stake in Teva Pharmaceutical Industries Ltd., holding over 57 million ordinary shares.